Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (6)

Medical Condition

  • Show all (833)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
    • (-) Amyloidosis (2)
  • Cancer (726)
    • Bladder Cancer (14)
    • Brain Cancer (25)
    • Breast Cancer (70)
    • Gastrointestinal (16)
    • Gynecologic Cancer (28)
    • (-) Head and Neck Cancer (4)
    • Kidney Cancer (8)
    • Leukemia (75)
    • Liver Cancer (10)
    • Lung Cancer (62)
    • Lymphoma (45)
    • Multiple Myeloma (30)
    • Pancreatic Cancer (22)
    • Prostate Cancer (36)
    • Sarcoma (25)
    • Skin Cancer (30)
    • Solid Tumors (42)
    • Thyroid Cancer (1)
    • Uveal Melanoma (7)
  • COVID-19 (Coronavirus) (1)
  • Diabetes (2)
  • Ear, Nose and Throat (1)
  • Endocrine & Metabolic Disease (1)
  • Gastrointestinal and Digestive Diseases (2)
  • Healthy Volunteers (8)
  • Liver Disease (1)
  • Neurological Disorders (31)
  • Obesity (1)
  • Obstetrics & Gynecology (6)
  • Pediatrics (42)
  • Psychiatric Disorders (1)
  • Surgery (1)
  • Transplant (3)
  • Urology (1)
Displaying 1 - 6 of 6

A study for patients with Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung cancer using study drug MGA271

Condition: Cancer / Head and Neck Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The study involves research about MGA271 in combination with Keytruda. MGA271 targets cancer cells that make a lot of a protein called B7-H3. Another way to say it is that the cells "overexpress" the protein. Very few normal cells express B7-H3. MGA271 is though to work by recognizing cancer…
Read More

Study of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Condition: Cancer / Head and Neck Cancer
Investigator: Matthen Mathew, MD
Status: Closed
The purpose of this study is to study ADU-S100 and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study aims to evaluate how safe and effective this drug combination is at treating your cancer. These drugs are thought to work by…
Read More

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Condition: Cancer / Head and Neck Cancer
Investigator: Matthen Mathew, MD
Status: Closed
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this…
Read More

Study of NBTRX3 in Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Condition: Cancer / Head and Neck Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to evaluate the safety and effectiveness (how well the study drug works) of NBTRX3 administered via intratumoral injections (injected directly into tumor) and used together with radiotherapy or radiotherapy combined with cetuximab, and how it compares with radiotherapy alone, or radiotherapy combined with cetuximab.…
Read More

Study For Previously Treated Patients Of Light-Chain Amyloidosis Using Study Drug Carfilzomib

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Read More

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science